中国临床新医学
中國臨床新醫學
중국림상신의학
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
2015年
5期
446-448
,共3页
序贯疗法%传统三联疗法%幽门螺旋杆菌%疗效
序貫療法%傳統三聯療法%幽門螺鏇桿菌%療效
서관요법%전통삼련요법%유문라선간균%료효
Sequential therapy%Traditional triple therapy%Helicobacter pylori( HP)%Curative effect
目的:观察临床应用序贯疗法与传统三联疗法根治幽门螺旋杆菌( HP )的效果。方法将2012-05~2014-05住院治疗的72例HP感染患者随机分为观察组和对照组各36例,对照组采用传统三联疗法治疗,观察组采用序贯疗法治疗,比较两组的临床疗效。结果治疗后,观察组的HP根除率为94.44%(34/36),优于对照组的77.78%(28/36),差异有统计学意义(P<0.05);观察组不良反应率为5.56%(2/36),对照组为11.11%(4/36),两组比较差异无统计学意义(P>0.05)。结论应用序贯疗法根治HP感染,疗效优于传统三联疗法,可选择为本地区根治HP的一线治疗方案。
目的:觀察臨床應用序貫療法與傳統三聯療法根治幽門螺鏇桿菌( HP )的效果。方法將2012-05~2014-05住院治療的72例HP感染患者隨機分為觀察組和對照組各36例,對照組採用傳統三聯療法治療,觀察組採用序貫療法治療,比較兩組的臨床療效。結果治療後,觀察組的HP根除率為94.44%(34/36),優于對照組的77.78%(28/36),差異有統計學意義(P<0.05);觀察組不良反應率為5.56%(2/36),對照組為11.11%(4/36),兩組比較差異無統計學意義(P>0.05)。結論應用序貫療法根治HP感染,療效優于傳統三聯療法,可選擇為本地區根治HP的一線治療方案。
목적:관찰림상응용서관요법여전통삼련요법근치유문라선간균( HP )적효과。방법장2012-05~2014-05주원치료적72례HP감염환자수궤분위관찰조화대조조각36례,대조조채용전통삼련요법치료,관찰조채용서관요법치료,비교량조적림상료효。결과치료후,관찰조적HP근제솔위94.44%(34/36),우우대조조적77.78%(28/36),차이유통계학의의(P<0.05);관찰조불량반응솔위5.56%(2/36),대조조위11.11%(4/36),량조비교차이무통계학의의(P>0.05)。결론응용서관요법근치HP감염,료효우우전통삼련요법,가선택위본지구근치HP적일선치료방안。
Objective To compare the efficacy of sequential therapy and the traditional triple therapy on he-licobacter pylori( HP) infection.Methods 72 patients with HP infection from May 2012 to May 2014, were random-ly divided into 2 groups, the control group and the observation group, with 36 cases in each group.The control group was performed traditional triple therapy and the observation group was performed sequential therapy.The clinical effect was compared between the two groups.Results The eradication rate of HP was 94.44%(34/36) in the obser-vation group and 77.78%(28/36) in the control group.There was significantly difference between the two groups(P<0.05).The adverse reaction rate was 5.56%(2/36) in the observation group and 11.11%(4/36) in the control group.There was no significantly difference between the two groups(P>0.05).Conclusion Sequential therapy is more effective in the treatment of HP infection than traditional triple therapy.